Replies to post #97924 on Biotech Values

[DewDiligence]

…you must mean the possibility of generic Lovenox

Correct. For Barron’s to write a couple of paragraphs about SNY’s valuation without even mentioning the possibility of Lovenox going generic in its largest market is tantamount to gross negligence, IMO.